Success Metrics

Completion Rate
0%(0/2)
Active Trials
2(50%)
Terminated
2(50%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(2)

Detailed Status

Active, not recruiting2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

active_not_recruiting250%
terminated250%

Recent Activity

2 active trials
Showing 4 of 4
active_not_recruitingphase_1

Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

NCT02993146
active_not_recruitingphase_1

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

NCT02381561
terminatedphase_2

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

NCT06359379
terminatedphase_1

Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer

NCT04406857

Clinical Trials (4)

Showing 4 of 4 trials
NCT02993146Phase 1

Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

Active Not Recruiting
NCT02381561Phase 1

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

Active Not Recruiting
NCT06359379Phase 2

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Terminated
NCT04406857Phase 1

Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4